Background: Primary progressive aphasia (PPA) is a clinical syndrome characterized by the neurodegeneration of language brain systems. Three main clinical forms (non-fluent, semantic, and logopenic PPA) have been recognized, but applicability of the classification and the capacity to predict the underlying pathology is controversial. We aimed to study FDG-PET imaging data in a large consecutive case series of patients with PPA to cluster them into different subtypes according to regional brain metabolism.Methods: 122 FDG-PET imaging studies belonging to 91 PPA patients and 28 healthy controls were included. We developed a hierarchical agglomerative cluster analysis with Ward's linkage method, an unsupervised clustering algorithm. We conduct...
International audienceObjective: To estimate the prevalence of amyloid positivity, defined by positr...
Background: Primary progressive aphasia (PPA) is a progressive language disorder associated with atr...
OBJECTIVE: To estimate the prevalence of amyloid-positivity, defined by PET/CSF biomarkers and/or ne...
<p>Background: Primary progressive aphasia (PPA) is a clinical syndrome characterized by the neurode...
Background and Objective: Primary progressive aphasia (PPA) is a clinical syndrome due to different ...
Importance:The ability to predict the pathology underlying different neurodegenerative syndromes is ...
IMPORTANCE The ability to predict the pathology underlying different neurodegenerative syndromes is ...
Objective: Alzheimer’s disease (AD) is found at autopsy in up to one third of patients with primary ...
Recently, diagnostic clinical and imaging criteria for primary progressive aphasia (PPA) have been r...
Purpose: A joint effort of the European Association of Nuclear Medicine (EANM) and the European Acad...
Clinical assessment of frontotemporal lobar degeneration (FTLD)/primary progressive aphasia (PPA) pa...
Objectives: Alzheimer’s disease (AD) is the cause of approximately 30% of cases of language onset de...
Primary progressive aphasia (PPA) encompasses the three subtypes nonfluent/agrammatic variant PPA, s...
Objective A new classification of primary progressive aphasia (PPA) was recently proposed to differe...
OBJECTIVE: To estimate the prevalence of amyloid positivity, defined by positron emission tomography...
International audienceObjective: To estimate the prevalence of amyloid positivity, defined by positr...
Background: Primary progressive aphasia (PPA) is a progressive language disorder associated with atr...
OBJECTIVE: To estimate the prevalence of amyloid-positivity, defined by PET/CSF biomarkers and/or ne...
<p>Background: Primary progressive aphasia (PPA) is a clinical syndrome characterized by the neurode...
Background and Objective: Primary progressive aphasia (PPA) is a clinical syndrome due to different ...
Importance:The ability to predict the pathology underlying different neurodegenerative syndromes is ...
IMPORTANCE The ability to predict the pathology underlying different neurodegenerative syndromes is ...
Objective: Alzheimer’s disease (AD) is found at autopsy in up to one third of patients with primary ...
Recently, diagnostic clinical and imaging criteria for primary progressive aphasia (PPA) have been r...
Purpose: A joint effort of the European Association of Nuclear Medicine (EANM) and the European Acad...
Clinical assessment of frontotemporal lobar degeneration (FTLD)/primary progressive aphasia (PPA) pa...
Objectives: Alzheimer’s disease (AD) is the cause of approximately 30% of cases of language onset de...
Primary progressive aphasia (PPA) encompasses the three subtypes nonfluent/agrammatic variant PPA, s...
Objective A new classification of primary progressive aphasia (PPA) was recently proposed to differe...
OBJECTIVE: To estimate the prevalence of amyloid positivity, defined by positron emission tomography...
International audienceObjective: To estimate the prevalence of amyloid positivity, defined by positr...
Background: Primary progressive aphasia (PPA) is a progressive language disorder associated with atr...
OBJECTIVE: To estimate the prevalence of amyloid-positivity, defined by PET/CSF biomarkers and/or ne...